Why the study?
Do inflammatory biomarkers (CRP, IL-6, NLR) predict outcomes and severity in patients with atrial fibrillation?
Do inflammatory biomarkers (CRP, IL-6, NLR) predict outcomes and severity in patients with atrial fibrillation?
Inflammatory biomarkers, particularly the neutrophil-lymphocyte ratio, show promise as simple and inexpensive tools for assessing prognosis and severity in atrial fibrillation.
NLR may aid AF prognosis assessment; leaves open routine adoption pending prospective validation.
Atrial fibrillation (AF) is the most common arrhythmia and is responsible for significant disease burden worldwide. Current evidence has suggested that systemic inflammatory response plays a crucial role in the initiation, maintenance, and progression of AF. So, recent efforts have been directed in search of measurable inflammatory biomarkers as additional tools in severity and prognosis assessment of AF. A simple, and easily obtainable, inflammatory marker is the neutrophil-lymphocyte ratio (NLR), which has shown good performance in preliminary studies as a potential prognostic biomarker in patients with AF. In this work, we performed a thorough review of clinical studies that evaluated the role of C-reactive protein (CRP), interleukin-6 (IL-6), and NLR as predictors of outcomes in AF. We gave a particular emphasis on the NLR because it is a simpler, widely available, and inexpensive biomarker.
No takes yet. Share an insight, caveat, or question.
Feliciano Chanana Paquissi (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: